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ess: graeme_currie@yaSummary Asthma is a common condition characterised by inflammation, airway
hyperresponsiveness and reversible airflow obstruction. Effective pharmacotherapy
must therefore be aimed at attenuating these underlying hallmark features. Despite
the use of regular low-to-moderate doses of inhaled corticosteroids, many patients
remain symptomatic and require further 2nd line controller therapy. The addition of
a concomitant long acting b2-agonist provides an effective means in which to
alleviate symptoms and reduce exacerbation frequency. Moreover, both agents can
be combined in a single inhaler, and provide patients with a more convenient and
effective way in which to deliver treatment to the endobronchial tree. This
evidenced-based review article discusses the effects of such combination inhalers
upon a variety of outcome parameters and their effects upon asthmatics across a
range of severities.
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Asthma is a common chronic heterogeneous condi-
tion which displays a complex and varied pheno-
typic picture. It can present in early childhood as
well as adulthood, and varies markedly in severity,
clinical course, subsequent disability and response
to treatment. Pathologically it is characterised by
inflammation, physiologically by airway hyperre-
sponsiveness (AHR) and consequent airflow obstruc-
tion, and clinically by wheeze, chest tightness,
breathlessness and cough.1 Symptoms are the final
manifestation of a complex interplay between an
array of inflammatory cells and mediators, which
cause airway smooth muscle to intermittently
contract and relax.
Apart from the short-term consequences of
troublesome symptoms, absence from work, hospi-
tal admissions and risks associated with an acute
exacerbation, long-term deleterious consequences
of asthma are well recognised. For example,
individuals with asthma have a more rapid rate of
decline in lung function than non-asthmatics2 and
previous studies have demonstrated that asth-
matics with impaired lung function experience a
higher mortality rate.3,4 Furthermore, if inflamma-
tion is left untreated, asthma can progress towards
a less reversible entity in which airways become
permanently narrowed along with thickening of
bronchial lumen walls.5
With the advent of fibreoptic bronchoscopy,
endobronchial biopsy, bronchoalveolar lavage and
sputum induction, it has become increasingly
recognised that inflammation is a fundamental
component in the pathophysiology of asthma. This
knowledge has highlighted the need for timely and
appropriate institution of anti-inflammatory ther-
apy directed towards the endobronchial tree.
Moreover, it has become apparent that in addition
to anti-inflammatory therapy, reversal of co-exi-
stant bronchospasm with the use of a long acting
b2-agonist (LABA) provides a commensurate im-
provement in asthma control. This evidenced-
based review examines the current literature in
terms of putative benefits of dealing concomitantly
with corticosteroid responsive inflammation and
reversible airflow obstruction with the combi-
nation of an inhaled corticosteroid plus LABA,
respectively.Inhaled corticosteroids
Inhaled corticosteroids are a vital component
in the successful treatment of persistent asthmaof all severities.6 Once bound to cytoplasmic
receptors concentrated in airway epithelial
and endothelial cells, they increase and de-
crease the gene transcription of anti-inflammatory
and pro-inflammatory mediators, respectively.
Corticosteroids also exert a direct inhibitory
effect upon a number of cells (eosinophils, T
lymphocytes and epithelial cells) implicated
in the asthmatic inflammatory process. As a
consequence, they attenuate AHR over several
weeks although the maximal effect may not
be achieved until after several months of regular
use.7 Moreover, inhaled beclomethasone and
fluticasone can prevent changes associated with
long-term unchecked inflammation (airway
remodelling).8,9
Dose–response studies using inhaled corticoster-
oids have generally been unable to demon-
strate any significant difference between individual
doses. For example, a meta-analysis by Holt
et al. evaluated 8 studies (2324 asthmatics) where
the effects of at least 2 doses of fluticasone
were measured.10 Most therapeutic gain (in
terms of airway calibre, symptoms and effects
upon exacerbations) was achieved at daily doses
of fluticasone between 100 and 250 mg. However,
the authors do acknowledge that the study was
limited by paucity of data with higher fluticasone
doses. It is also important to note that clinical
outcome measures such as lung function, rescue
medication use and symptoms fail to provide
information regarding the intrinsic disease process
itself and tend to be downstream markers rela-
tively remote from AHR and underlying inflamma-
tion.1 Indeed, using AHR as the primary outcome
measure, a meta-analysis of 25 studies (963
patients) demonstrated that high doses (X1000 mg
of beclomethasone or equivalent) of inhaled
corticosteroid did confer greater improvements in
terms of attenuating AHR than low doses
(o1000 mg).11 It is pertinent to be aware that this
is at the expense of adverse local and systemic
sequelae. However, patients with severe persistent
asthma appear to be protected from high doses of
inhaled corticosteroids due to decreased lung
bioavailability as a consequence of reduced airway
diameter.12,13
Adverse effects of inhaled corticosteroids tend to
occur in a dose-dependant way.14 Clinicians should
therefore aim to have patients controlled on the
lowest dose of inhaled corticosteroid which opti-
mises airway benefit and minimises the risk of
systemic adverse effects, thus improving the over-
all therapeutic ratio. Indeed, it is generally
accepted that at daily doses greater than 800 mg
of beclomethasone or equivalent in adults, the
ARTICLE IN PRESS
Effects of dual therapy with corticosteroids plus long acting b2-agonists in asthma 685dose–response curve for desired effects becomes
flat, while that for systemic adverse effects
becomes steep.15 Moreover, the relative flatness
of the dose–response curve in terms of forced
expiratory volume in 1 s (FEV1) with inhaled
corticosteroids suggests that concomitant treat-
ment which maximally relaxes airway smooth
muscle—especially in patients with impaired lung
function—may be the way ahead in terms of
optimal asthma control.Long acting b2-agonists
LABAs were introduced in the early 1990s as an
addition to the pharmacological armamentarium
involved in the control of asthma. LABAs have two
clinically important properties, namely a broncho-
dilator effect in the presence of low bronchomotor
tone and a protective effect in the presence of
increased bronchomotor tone (so-called functional
antagonism). Functional antagonism can be eval-
uated by performing bronchial challenge tests and
provides a way of assessing the protective effects
of b2-agonists in the laboratory. Furthermore,
bronchoprotection with LABAs can be considered
to be a surrogate for airway stabilisation upon
smooth muscle.16 They have also been shown to
suppress the release of inflammatory mediators
from primed mast cells in the airway,17,18 reduce
plasma exudation from airway endothelium19,20 and
block bronchoconstricting sensory nerve activation
in guinea pig bronchi.21
Currently, salmeterol and eformoterol are
the most commonly used LABAs in clinical pra-
ctice. Both bind to airway smooth muscle b2-
adrenoceptors and demonstrate a broncho-
dilating effect in excess of 12 hours after a
single inhalation.22 In contrast to short acting b2-
agonists, LABAs are highly lipophilic which partly
explains their prolonged duration of action.23
The dose–response curve for salmeterol is rela-
tively flat when 50 mg is exceeded, whereas
eformoterol exhibits a dose-dependant relationship
in terms of bronchoprotection to inhaled metha-
choline at doses up to 120 mg.24 Salmeterol is a
partial agonist and has a slower onset of action,
while in contrast, eformoterol is a full agonist
and demonstrates a quicker onset of bronchodila-
tion. This pharmacological property can be
exploited, allowing eformoterol to be used on an
‘as required basis’. For example, in a 12 week,
double blind, parallel group study, eformoterol
4.5 mg was shown to confer superior asthma control
than terbutaline 0.5mg when used for intermittent
acute relief of symptoms.25It is important to be aware that LABAs do not
exhibit in vivo anti-inflammatory activity.26–28 For
example, Lazarus et al. evaluated well controlled
asthmatics using triamcinolone 800 mg/day and
randomly switched them to receive salmeterol as
monotherapy or continue with triamcinolone.29
Patients assigned the former group experienced
more exacerbations and demonstrated an increase
in sputum and blood inflammatory markers. In
another trial, Lemanske et al. randomised patients
after a 6-week run-in not controlled on triamcino-
lone 800 mg/day, to receive either salmeterol or
placebo.30 During the next 4 months, inhaled
corticosteroids were discontinued in the entire
placebo group and in one-half of the salmeterol
group. The mean overall treatment failures with
either salmeterol or placebo were similar in both
groups. In other words, add on salmeterol had no
effects on disease control following discontinuation
of triamcinolone. As a consequence, guidelines do
not advocate the use of LABAs as monotherapy in
asthmatics of any severity.6
Polymorphisms of the b2-adrenoceptor have been
identified, of which substitution of glycine for
arginine at codon 16 (occurring in about 40% of
the UK population), enhances the susceptibility to
down regulation by b2-agonists. Due to prolonged
receptor occupancy, the b2-adrenoceptor becomes
internalised and degraded. As a result, an attenu-
ated bronchoprotective response can be observed
with different types of inhaled stimuli.31,32 Further-
more, in the clinical setting of an acute asthma
attack, it may be relevant that a blunted response
to inhaled salbutamol occurs with chronic treat-
ment with LABAs.33 However, there is little compel-
ling evidence to suggest that tolerance develops to
the bronchodilator effects of LABAs.Corticosteroids and long acting b2-
agonists used in combination
The use of an inhaled corticosteroid combined with
a LABA in a single device is becoming an increas-
ingly popular method of delivering drugs to the
lung. Indeed, commonsense suggests that this is a
reasonable pharmacological and financial option
since inhaled corticosteroids are the most potent
anti-inflammatory agents and LABAs the most
potent bronchodilators used in asthma. Currently,
salmeterol can be given with fluticasone in a single
inhaler (Seretide), and eformoterol has been
formulated with budesonide (Symbicort; Table 1).
This has the potential advantage of improving
patients compliance in view of fewer inhalations
ARTICLE IN PRESS
Table 1 Symbicort and Seretide constituents, doses, devices and adult dosing regimes.
Inhaled
corticosteroid dose
Long acting b2-
agonist dose
Device Dosing regime
Symbicort 100/6 Budesonide 80 mg Eformoterol 6mg Turbohaler 1-2 inhalations once or twice daily
Symbicort 200/6 Budesonide 160 mg Eformoterol 6mg Turbohaler 1-2 inhalations once or twice daily
Seretide 50 Fluticasone 50 mg Salmeterol 25 mg Evohaler 2 inhalations once or twice daily
Seretide 125 Fluticasone 125 mg Salmeterol 25 mg Evohaler 2 inhalations twice daily
Seretide 250 Fluticasone 250 mg Salmeterol 25 mg Evohaler 2 inhalations twice daily
Seretide 100 Fluticasone 100 mg Salmeterol 50 mg Accuhaler 1 inhalation twice daily
Seretide 250 Fluticasone 250 mg Salmeterol 50 mg Accuhaler 1 inhalation twice daily
Seretide 500 Fluticasone 500 mg Salmeterol 50 mg Accuhaler 1 inhalation twice daily
G.P. Currie et al.686and inhaler devices required, while the fairly
immediate bronchodilation especially with
eformoterol,24 provides patients with an instant
boost. Furthermore, the fact that the two
moieties are inseparable, implies that comp-
liance with anti-inflammatory therapy might
be enhanced as the LABA (which the patient
perceives as beneficial shortly after dosing)
cannot be used at the expense of inhaled corticos-
teroid.Possible drawbacks
Despite the advantages of a single inhaler, on a
practical level altering the inhaled corticosteroid
dose, without altering the LABA dose, becomes less
straightforward. This has the potential conse-
quence that patients may remain on unnecessary
or insufficient doses of anti-inflammatory treat-
ment for a prolonged period of time. Indeed, due to
the variable nature of asthma, patients are advised
to adjust their inhaled corticosteroid dose accord-
ing to symptoms and personal best peak expiratory
flow (PEF).6 An evidenced-based review by Gibson
and Powell highlighted the benefit of written action
plans—involving at least doubling the inhaled
corticosteroid dose—when incorporated into the
routine care of asthmatic patients.34 During periods
of deteriorating asthma control, patients using a
Seretide Accuhaler would therefore require a
separate inhaler in order to titrate upwards the
dose of fluticasone. Similarly, when asthma is well
controlled and ‘‘step-down’’ considered appropri-
ate, patients would have to consult their primary
care physician to be provided with a further inhaler
containing less corticosteroid. In order to overcome
this difficulty, Symbicort—largely due to the less
steep dose–response curve of eformoterol com-pared to salmeterol24—can be used in a more
flexible manner. This allows different corticoster-
oid doses to be delivered to the lung along with a
variable dose of eformoterol. Indeed, in a study by
Aalbers et al.,35 an adjustable maintenance dose of
twice daily budesonide 160 mg plus eformoterol (in
a single inhaler) was shown to provide effective
asthma control when individuals were instructed to
titrate treatment according to symptoms. More-
over, when compared to a fixed fluticasone plus
salmeterol dosing regime, there were 40%
(P ¼ 0:018) fewer exacerbations.
Considerable concern has been focused on the
use of LABAs and the masking of underlying airway
inflammation. Theoretically, patients may use such
drugs for relatively instant bronchodilation and
adhere less stringently to inhaled corticosteroid
therapy (when used as separate inhalers). This in
turn could result in persisting chronic mucosal
inflammation of which the patient is unaware, in
turn paving the way towards an exacerbation.
Indeed, in a study by McIvor et al., the use of
salmeterol controlled symptoms and maintained
bronchodilation but resulted in an increase of
sputum eosinophils when inhaled corticosteroids
were tapered in 13 asthmatics.36 This small study of
patients using daily doses of inhaled corticosteroid
X1500 mg may not be applicable to ‘‘real-life’’, as
doses were reduced until either criteria for an
exacerbation was reached or until no corticoster-
oids were being used at all. In another study, after a
run-in using budesonide 1600 mg/day, 60 moder-
ately severe asthmatics were randomised to re-
ceive budesonide 800 mg/day (mean FEV1 82%
predicted) or budesonide 200 mg/day plus eformo-
terol (mean FEV1 84% predicted).
37 After 1 year of
randomised treatments, there were no differences
in either surrogate markers of inflammation and
perhaps surprisingly of lung function. Thus, this
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terms of underlying inflammation in patients using
a four-fold smaller corticosteroid dose in conjunc-
tion with a LABA.Effects of long acting b2-agonists as add-
on therapy to inhaled corticosteroids
Mild asthmatics
Inhaled corticosteroids are advocated to be used as
1st line controller therapy in persistent asthmatics
over and above intermittent short acting b2-
agonists.6 Moreover, regular use of short acting
b2-agonists demonstrates no benefit in long term
asthma control.38–40 However, the question of
whether mild persistent asthmatics now should be
treated with inhaled corticosteroids in combination
with LABAs arises, mainly in recognition of their
demonstrated beneficial effects in patients with
more severe disease over anti-inflammatory ther-
apy as monotherapy.41
A study by O’Byrne et al. evaluated the effects of
placebo, budesonide 200 mg/day as monotherapy or
combined with eformoterol in 698 corticosteroid
naı¨ve asthmatics.42 Symptomatic patients had a
mean FEV1 of approximately 90% predicted in all
three randomised groups. After 1 year of treat-
ment, those receiving budesonide alone had a 60%
and 48% reduction in risk of first severe asthma
exacerbation and rate of poorly controlled asthma
days, respectively, compared to placebo. Budeso-
nide treated patients also benefited from a reduc-
tion in symptoms and increase in FEV1. Compared
to inhaled corticosteroid alone, concomitant treat-
ment with eformoterol conferred no other im-
provement other than significant (although unlikely
to be clinically so) small improvements in FEV1
(1.8% predicted, P ¼ 0:023) and PEF (15 L/min,
P ¼ 0:0001). In the same study, 1272 mild asth-
matics usingp400 mg/day of inhaled corticosteroid
were randomised to receive budesonide 200 mg/
day, budesonide 200 mg/day plus eformoterol,
budesonide 400 mg/day or budesonide 400 mg/day
plus eformoterol. In these symptomatic patients
(mean FEV1 of approximately 86% predicted), the
addition of eformoterol to either budesonide dose
reduced the risk of first asthma exacerbation by
43% and poorly controlled asthma days by 30%,
respectively. Adding eformoterol to budesonide
200 mg/day was more effective than doubling the
dose of the latter in terms of asthma control.
Another study evaluated the effects of add-on
eformoterol in mild patients receiving o400 mg/day of beclomethasone or equivalent.43 In this
multi-centre study, 663 symptomatic mild asth-
matics (mean PEF 74% predicted) were randomised
to receive budesonide 800 mg/day plus either
eformoterol or placebo. After 4 weeks, patients
whose asthma was well controlled (n ¼ 505) were
randomised again to receive budesonide 400 mg/day
plus eformoterol or placebo for further 6 months. It
was discovered that the addition of eformoterol to
either dose of budesonide resulted in more effec-
tive control of asthma. However, it is relevant to
point out that comparison of additional effects of
the LABA were only being made to placebo (and not
for example a higher inhaled corticosteroid dose or
alternative 2nd line controller). In another study,44
the combination of fluticasone 200 mg/day plus
salmeterol was compared to fluticasone 200 mg/
day alone in patients (mean PEF of around 80%
predicted) only using short acting b2-agonists for as
required use. Compared to fluticasone alone,
combination therapy conferred significant improve-
ments in terms of daytime symptom scores and
diurnal PEF over a 24 week period. No differences
were observed in nighttime symptoms or frequency
of short acting b2-agonist use. Moreover, it is
relevant to point out that no assessment of under-
lying inflammation or AHR was made, while a third
randomised limb evaluating the comparative ef-
fects of double the dose of fluticasone (400 mg/day)
would have been of potential interest.
In mild asthmatics there is generally a paucity of
data concerning the use of LABAs in conjunction
with inhaled corticosteroids with the consequence
that definite conclusions are difficult to make.
However, it is reasonable to believe that such
patients with essentially normal lung function,
should continue to be treated with an inhaled
corticosteroid alone; those with persistent symp-
toms (and especially with impaired lung function)
could proceed to have a therapeutic trial of LABA.
However, further trials are required to compare the
effects of initiating asthma treatment with an
inhaled corticosteroid alone versus add-on LABA
especially in mild asthmatics with both completely
normal and also mildly impaired lung calibre.
Ideally these should evaluate effects upon a variety
of endpoints such as symptoms, lung function,
biomarkers of airway inflammation, AHR and airway
remodelling.Moderate to severe asthmatics
An important early study into the use of LABAs
evaluated 429 asthmatics uncontrolled on beclo-
methasone 400 mg/day.45 Individuals were rando-
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existing inhaled corticosteroid dose (1000 mg/day)
or add-on treatment with salmeterol for 6 months.
Patients using concomitant LABA demonstrated
greater lung function and fewer symptoms than
those using inhaled corticosteroid alone, although
no difference in exacerbation rates were observed
between the two groups. It is also important to
note that effects upon surrogate biomarkers of
inflammation or AHR were not measured. In
another study, Woolcock et al. randomised 738
asthmatics not controlled on beclomethasone
1000 mg/day to receive either double their inhaled
corticosteroid dose, or addition of twice daily
salmeterol 50 mg or 100 mg.46 No differences were
observed upon exacerbation rates or AHR in all
three groups, but patients who were treated with
either dose of LABA benefited from fewer symp-
toms and a greater PEF. In the multicentre study by
Pauwels et al.,47 optimising the inhaled corticos-
teroid dose to 800 mg/day of budesonide and then
adding eformoterol, resulted in a significantly
reduced number of severe exacerbations compared
to adding eformoterol to 200 mg/day of budesonide
(a 49% versus 26% reduction, respectively). In other
words, budesonide reduced exacerbations by its
anti-inflammatory effect, while eformoterol pro-
duced a further reduction by stabilising airway
smooth muscle in patients using the higher bude-
sonide dose. In the same study, there was also a
disconnect between lung function and exacerba-
tions; in other words, despite a reduction in
exacerbations, FEV1 and PEF were unchanged when
comparing budesonide 200 mg/day versus budeso-
nide 800 mg/day. This indicates that when optimis-
ing the dose of inhaled corticosteroid, lung function
is relatively distant from the underlying inflamma-
tory process and despite no change in value,
further beneficial clinical effects may actually be
apparent. Thus, while endpoints such as lung
function are of undoubted value, clinicians must
not lose sight of the basic pathophysiological
hallmarks of the asthma syndrome (i.e. AHR and
inflammation) along with the impact of asthma
pharmacotherapy upon exacerbations.
In a meta-analysis (n ¼ 9 trials, 3685 patients),
Shrewsbury et al. evaluated the effects of in-
creasing the dose of inhaled corticosteroid
versus the addition of salmeterol.41 Add on therapy
with LABA tended to be superior on most lung
function endpoints and symptoms. However, de-
spite no trial included in the meta-analysis
conferring a significant reduction in exacerbations,
there was a small but significant reduction
(2.4%) in severe exacerbations on pooling of the
results.Interactions between inhaled
corticosteroids and long acting
b2-agonists
Despite knowledge that co-administered inhaled
corticosteroids plus LABAs are superior to doubling
the dose of the former in terms of asthma control,
it has previously been considered that both agents
work independently of one another. In other words,
inhaled corticosteroids exert potent anti-inflam-
matory effects while the LABA moiety relaxes
airway smooth muscle. However, recent studies
have demonstrated that beneficial synergism may
occur on a molecular and histological basis.
Roth et al. evaluated the effects of budesonide
and eformoterol (alone and in combination) upon
transcription factors and cell proliferation.48 The
combination of inhaled corticosteroid plus LABA
provided a synergistic effect upon transcription
factors and an inhibitory effect on smooth muscle
cell proliferation. In another study, salmeterol
enhanced the activation of the glucocorticoid
receptor in primary human lung fibroblasts and
vascular smooth muscle cells.49 In a placebo
controlled study involving 45 symptomatic asth-
matics receiving inhaled corticosteroids, the ef-
fects of supplemental salmeterol was examined in
by way of changes in bronchial biopsy material.50
Patients treated with a LABA showed a significant
reduction in blood vessel density in lamina propria
which the authors suggested could have been as a
direct consequence of modifications of angiogenic
growth factors.
Conversely, corticosteroids have been shown to
influence the effects of b2 adrenergic receptors.
For example, they can regulate b2 adrenergic
receptor function by increasing its expression
through gene transcription.51 Moreover, they also
demonstrate an inhibitory effects upon G–protein
coupling and b2 adrenergic receptor downregula-
tion, and in turn desensitisation.52
In light of these observations, it can be seen
that there is interplay between both moieties
on a molecular level, however there is far less
convincing evidence that the observed synergy
between inhaled corticosteroids and LABA actually
translates into ‘‘real-life’’ benefit. For example,
in a randomised controlled crossover study in
mild-to-moderate asthmatics (mean FEV1 80%
predicted), fluticasone 500 mg/day plus salmeterol
was compared to double the dose of fluti-
casone alone. The latter treatment conferred
significant superiority in terms of surrogate
inflammatory markers comprising of adenosine
monophosphate threshold concentration and
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Figure 1 Absolute geometric mean (geometric standard
error (SE)) (a) adenosine monophosphate threshold con-
centration (AMP PC20) and (b) exhaled nitric oxide at
baseline and after treatment with twice daily fluticasone
propionate 500 mg alone (FP; hatched bars) and twice
daily fluticasone propionate 250 mg/salmeterol 50 mg
combination inhaler (FP+SM; double hatched bars).
*Denotes significant (Po0:05) difference from baseline,
y denotes significant (Po0:05) difference between
randomised treatments. Reproduced with permission
from Currie et al.62
Figure 2 Scatterplots showing individual differences and
geometric means (geometric SE) following treatment with
twice daily fluticasone propionate 250 mg/salmeterol
50 mg combination inhaler (circles) and fluticasone
propionate 250 mg (triangles) for: (a) adenosine mono-
phosphate threshold concentration (AMP PC20) threshold
and (b) blood eosinophils. No differences were observed
between mean values. Reproduced with permission from
Currie et al.63
Effects of dual therapy with corticosteroids plus long acting b2-agonists in asthma 689exhaled nitric oxide (Fig. 1). In another study,
fluticasone 500 mg/day plus salmeterol in combina-
tion was no different from fluticasone 500 mg/day
alone on exhaled nitric oxide, adenosine monopho-
sphate threshold concentration and blood eosino-
phils (Fig. 2).
Thus, while data of Roth48 and Eickelberg49 show
interesting in vitro observations to suggest a
positive and beneficial interaction between the
two moieties, this has not been substantiated by in
vivo work. Nonetheless, inhaled corticosteroids and
LABAs do provide complementary effects on in-
flammation and smooth muscle dysfunction, re-
spectively, which frequently results in improved
asthma control when taken together.Comparison of add on long acting b2-
agonists versus other 2nd line agents
Prior to escalation of treatment, symptomatic
asthmatics should have inhaler technique checked
and compliance assessed, along with an effort to
look for co-existent conditions such as allergic
rhinitis or gastro-oesophageal reflux disease which
may be contributing to symptoms. After doing so,
current guidelines suggest that in asthmatics not
controlled on a low-to-medium dose of inhaledcorticosteroid (400–800 mg/day of beclomethasone
or equivalent) a therapeutic trial of add-on LABA
should be considered (step 3).6 Only in patients
who subsequently remain symptomatic (step 4) or
derive no benefit from the addition of a LABA, the
addition of a leukotriene receptor antagonist
(LTRA) or theophylline should be considered.
Table 2 shows the relative properties of possible
2nd line controller therapies.Leukotriene receptor antagonists
Despite transforming asthma management, inhaled
corticosteroids do not suppress all aspects of
inflammation. For instance, it has become apparent
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Table 2 Relative effects of 2nd line add-on therapies to inhaled corticosteroids: ++,+ and 0 represent, marked,
some and no effects, respectively.
Long acting b2-agonist Leukotriene receptor
antagonist
Theophylline
Orally active No Yes Yes
Anti-inflammatory properties 0 + +
Effects upon airway
hyperresponsiveness
+ (‘‘airway stabilising
effect’’)
+ +
Bronchodilator properties ++ + +
G.P. Currie et al.690that eosinophilic inflammation can persist despite
high doses of inhaled corticosteroids,53,54 while oral
corticosteroids can cause an increase in the number
of neutrophils.55 It is also of potential therapeutic
importance that inhaled corticosteroids have a
limited impact on the synthesis or release of
cysteinyl leukotrienes.56,57
The cysteinyl leukotrienes (C4, D4 and E4) are
lipid mediators which are implicated in producing
an array of effects such as bronchoconstriction,
increased vascular permeability, mucous secretion,
inflammatory cell recruitment and airway smooth
muscle proliferation. Antagonism of the effects of
cysteinyl leukotrienes can be achieved by drugs
preventing their synthesis using a 5-lipoxygenase
inhibitor, or blocking specific leukotriene receptors
using a LTRA. Currently two LTRAs are licensed for
clinical use in Europe, namely montelukast and
zafirlukast. These drugs demonstrate bronchodila-
tor and anti-inflammatory properties and can
attenuate AHR to a variety of bronchoconstrictor
stimuli.58 A further therapeutic benefit is that
LTRAs exert their effects following single doses
and are orally active. This latter property may
enhance compliance especially in children, adoles-
cents and the elderly in whom technical difficulties
associated with and dislike of inhaled medication
may occur. Furthermore, unlike LABAs, tolerance to
their bronchoprotective effects has not been
demonstrated.
A number of studies have performed head-to-
head comparisons of add-on therapy with a LTRA
compared to LABA in uncontrolled asthmatics using
inhaled corticosteroids alone. In a double blind,
double dummy, parallel group, multicentre trial
over 12 weeks, it was demonstrated that the
addition of salmeterol was superior to that of
add-on montelukast 10mg/day in uncontrolled
asthmatics using inhaled corticosteroids.59 This
was in terms of measures of lung calibre (the
primary endpoint), salbutamol use and symptom
scores. Similarly, in a multi-centre trial, Nelson et
al. demonstrated that adding salmeterol to fluti-casone was superior to concomitant treatment with
zafirlukast 20mg twice daily.60 Indeed, compared
with oral zafirlukast, treatment with salmeterol
conferred significantly greater improvements in
pulmonary function, relief of both daytime and
nighttime asthma symptoms and Asthma Quality of
Life Questionnaire. It is pertinent to consider that
in these studies, the primary endpoint was lung
function which in turn can be considered as being
‘‘smooth muscle dependant’’, or in other words,
one in which the effects of a LABA would likely be
greater than those of a LTRA.
Two more recent studies have examined the
effects of add-on LABA or LTRA in terms of
exacerbation frequency. For example, 1490 chronic
asthmatics uncontrolled on inhaled fluticasone
200 mg/day, were randomised to receive add-on
montelukast 10mg/day or salmeterol.61 After a
year of treatment, 20.1% of patients in the
montelukast group compared with 19.1% in the
salmeterol group experienced an exacerbation of
asthma, with no significant difference between
randomised treatments. However, salmeterol trea-
ted patients had a greater FEV1 and morning PEF
(Pp0:001), while the combination of fluticasone
plus montelukast conferred a greater reduction
(P ¼ 0:011) upon blood eosinophils than add-on
salmeterol. Moreover, similar to previous in vivo
data,62,63 no potentiation of the anti-inflammatory
effects of inhaled corticosteroids by the LABA
moiety was observed in this study. In another
multi-centre study using 1473 symptomatic asth-
matics, the effects of add-on montelukast 10mg/
day or salmeterol to fluticasone 220 mg/day were
evaluated.64 After 48 weeks, no significant differ-
ence in exacerbation frequency was observed
between treatments. However, salmeterol im-
proved lung function and symptom scores to a
greater extent than montelukast, although the
latter provided significantly greater effects upon
blood eosinophils.
It can therefore be seen that in trials evaluating
the addition of a LABA or LTRA, the choice of
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treatment confers superiority. Moreover, many
trials in asthmatics have a prerequisite to entry of
reversibility of 15% to short acting bronchodilator,
irrespective of extent of underlying inflammation
or AHR. While this is one of the classical feature in
the diagnosis of asthma, it may not be representa-
tive of the asthmatic population at large and is not
crucial in making the diagnosis.6 Indeed, many
symptomatic asthmatics demonstrate preserved
lung function which in turn suggests that underlying
inflammation and AHR are the driving forces behind
symptoms and exacerbations.65,66 It remains to
been whether in future updated guidelines the
addition of a LTRA to a low-to-moderate inhaled
corticosteroid dose sits more comfortably beside
add-on LABA.Theophyllines
Theophyllines are phosphodiesterase inhibitors
which have some additional effect in asthmatics
when added to inhaled corticosteroids. They are
weak bronchodilators and possess some anti-in-
flammatory action. Their use is frequently limited
due to concerns of cardiac arrhythmias, gastro-
intestinal upsets and the need for monitoring
plasma levels due to a narrow therapeutic index.
Moreover, there is considerable variation in the
half-life of theophyllines and care requires to be
taken in for example, smokers, patients with liver
disease or heart failure and those taking certain
drugs. A meta-analysis (n ¼ 9 trials, 1330 patients)
directly compared the effects of theophylline
versus salmeterol in asthmatics and concluded that
the use of a LABA was significantly superior in terms
of lung function and symptoms along with a more
favourable adverse effect profile.67Conclusions
The use of an inhaled corticosteroid plus LABA in a
single inhaler is likely to continue to increase in
popularity in view of its convenience, efficacy and
beneficial effects upon exacerbation reduction.
Moreover, this provides patients with a convenient
and effective treatment which deals concomitantly
with suppression of underlying inflammation and
relaxation of bronchial smooth muscle. Patients are
also likely to prefer this option, as compared to a
higher inhaled corticosteroid dose, in view of
better symptom control plus reducing the risk of
local and systemic adverse sequelae.Initial concerns regarding the problem of masking
underlying inflammation with the LABA moiety has
not been substantiated to any great degree.
However, there are few data comparing their
effects versus higher doses of inhaled corticoster-
oids in terms of airway remodelling. Indeed, in a
study by Ward et al.,68 significant reductions in
basement membrane thickness did not occur until
after 3 months of high dose inhaled corticosteroid
treatment (1500 mg/day of fluticasone). Moreover,
Reddel et al.69 demonstrated that patients starting
with 3200 mg/day of budesonide had greater nor-
malisation in AHR and fewer exacerbations
than even 1600 mg/day of budesonide. It is
therefore important to ensure that untoward
long-term sequelae do not occur at the expense
of short-term superior bronchodilation with the use
of LABAs. Further prospective studies incorporating
surrogate inflammatory biomarkers and parameters
reflecting airway remodelling are therefore re-
quired to fully evaluate the effects of combination
inhalers versus, for example, double the inhaled
corticosteroid dose.
It is also important for prescribing clinicians to be
aware of the relative lack of data advocating their
use in patients with very mild—although persis-
tent—disease, especially when lung function (FEV1)
is not compromised. In other words, in many such
patients airway calibre cannot be further improved
and it is in fact the underlying airway inflammation
and AHR which requires treatment with anti-
inflammatory therapy to alleviate symptoms. More-
over, perhaps in these patients who have persistent
symptoms despite the use of a low-to-moderate
inhaled corticosteroid dose, the addition of a LTRA
might be the more sensible pharmacological inter-
vention in view of beneficial effects upon attenu-
ating AHR and inflammation.
In more severe patients, the study by Pauwels
succinctly demonstrated the benefits of optimising
the inhaled corticosteroid dose to 800 mg/day of
budesonide, prior to introduction of a LABA.47 It is
important to be aware however that there is a
degree of interindividual variability in terms of
response to inhaled corticosteroids. In other words,
not all asthmatic patients require the same inhaled
corticosteroid dose in which to suppress inflamma-
tion to a satisfactory degree and therefore at which
point further 2nd line therapy is required for
persistent symptoms varies. Indeed, the problem
with conventional measures of asthma control
remains the fact that they are distant from the
pathophysiological hallmarks and merely reflect
the clinical consequences of a cascade of complex
cellular events. Moreover, ‘‘mean patients’’ are
often created from the findings of multi-centre
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Table 3 Characteristic features of the ideal surrogate inflammatory marker in asthma.
Raised only in asthma
Raised only when endobronchial inflammation is present
Simple and cheap to measure
Easy to measure in primary and secondary care settings
Patient acceptability
Linear reduction on institution of anti-inflammatory therapy with clear cut dose-response effect
Demonstrated to provide superior clinical control when used along with conventional measures than the latter
alone
G.P. Currie et al.692randomised controlled trials and meta-analysis, the
results from which have been derived from many
thousands of individuals across a range of socio-
economic backgrounds, asthma phenotype, age and
racial background.
To overcome these difficulties in an ideal world,
clinicians would have access to a reliable surrogate
inflammatory biomarker (Table 3). This in turn
would provide information as to when exactly
corticosteroid responsive inflammation was ade-
quately suppressed and when additional 2nd line
controller therapy such as a LABA to maximally
dilate the airway should be instituted. For exam-
ple, in a study by Green et al., an asthma
management strategy targeted against a surrogate
inflammatory marker (sputum eosinophils) led to
significantly fewer severe asthma exacerbations
than using standard guidelines alone.70 Moreover,
the effects on eosinophils and other inflammatory
markers were dissociated from lung function and
symptoms. However, the practicality of performing
sputum induction in everyday clinical practice,
especially in terms of obtaining instant feedback of
the result for the patient in the clinic is question-
able. Perhaps in the future, clinicians will have
ready access to a convenient tool in which to
monitor the extent of underlying airway inflamma-
tion, help tailor pharmacotherapy to individual
patients and in turn reduce the burden of asthma in
both primary and secondary care.References
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